Partners
The FinnGen research project involves all the same actors as drug development: universities, hospitals, biobanks and pharmaceutical companies. With this open cooperation, we hope to speed up the emergence of new innovations.
Coordinating organizations:
University of Helsinki (Institute for Molecular Medicine Finland, FIMM) is coordinating the FinnGen study. Helsinki Biobank (the Hospital District of Helsinki and Uusimaa) coordinates the sample collection and THL coordinates the processing of register data.
Funded by:

and the funding research partners:
AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Celgene/Bristol-Myers Squibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck, Novartis, Pfizer and Sanofi.
THE PROJECT INVOLVES THE FINNISH BIOBANK COOPERATIVE (FINBB) AND THE FOLLOWING FINNISH BIOBANKS AND THEIR PARENT ORGANIZATIONS:
Auria Biobank (consortium partners: Wellbeing Services County of Southwest Finland & University of Turku), Northern Finland Biobank Borealis (consortium partners: Wellbeing Services County of North Ostrobothnia & University of Oulu), Arctic Biobank (consortium partner: University of Oulu), Central Finland Biobank (consortium partners: Wellbeing Services County of Central Finland & University of Jyväskylä), Finnish Clinical Biobank Tampere (consortium partners: Wellbeing Services County of Pirkanmaa & Tampere University Foundation sr), Biobank of Eastern Finland (consortium partners: Wellbeing Services County of North Savo & University of Eastern Finland), Helsinki Biobank (consortium partner: HUS Group, the joint authority for Helsinki and Uusimaa), THL Biobank (consortium partner: The Finnish Institute for Health and Welfare), FRC Blood Service Biobank (consortium partner: The Finnish Red Cross Blood Service), Hematological Biobank, Finnish Biobank Cooperative (FINBB)